Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Myeloablative and immunoablative therapy followed by autologous hematopoietic stem cell transplantation (AHSCT) has been shown to be effective in patients with highly active relapsing multiple sclerosis (RMS) with continued activity despite treatment with approved disease-modifying therapies (DMTs). However, AHSCT has not been formally compared to the contemporary high efficacy biologic DMTs in a clinical trial.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: George E. Georges, Jeffrey A Cohen, Linda M. Griffith, Kati Steinmiller, Bill Barry, Kristina Harris, Kristin Ryker, Janis Rice, Patti Tosta, Sean McCarthy, Julia S Goldstein, James McNamara, Deborah Miller, Joshua J Carlson, Douglas L Arnold, Dawn E Smil Tags: 454 Source Type: research